Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn
Chronic liver disease and associated cirrhosis account for one million deaths every year
Read Moreby Jen Brogan | Apr 23, 2024 | News | 0
Chronic liver disease and associated cirrhosis account for one million deaths every year
Read Moreby Jen Brogan | Jan 10, 2024 | News | 0
The £30m ADVANCE study is the most extensive study into liver disease worldwide
Read Moreby John Pinching | Apr 21, 2023 | News | 0
Companies will collaborate to boost novel treatments for individuals with geographic atrophy
Read Moreby John Pinching | Feb 8, 2023 | News | 0
The treatment has been developed to treat certain chronic heart failure patients and is approved elsewhere
Read Moreby John Pinching | Aug 3, 2022 | News | 0
Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies
Read Moreby John Pinching | Jul 12, 2022 | News | 0
The partnership will deliver digital therapy support for asthma and COPD patients
Read Moreby John Pinching | Mar 7, 2022 | News | 0
Largest unmet need in cardiovascular medicine finally receives approved therapy
Read Moreby John Pinching | Mar 1, 2022 | News | 0
Sensor development project marks the fifth joint research effort between BioMed X with Boehringer Ingelheim
Read Moreby Lucy Parsons | Jul 7, 2021 | News | 0
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
Read Moreby Lucy Parsons | Jun 22, 2021 | News | 0
First oral blood thinning drug approved for paediatric patients in the US
Read Moreby Lucy Parsons | Jan 15, 2021 | News | 0
Agreement will leverage Enara’s novel Dark Antigen discovery platform
Read Moreby Lucy Parsons | Jan 11, 2021 | News | 0
Partnership will aim to research and implement quantum computing in pharma R&D
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479